{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:27:58Z","timestamp":1787041678735,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41401-026-01843-4","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T02:13:52Z","timestamp":1780884832000},"page":"2682-2691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic checkpoint blockade of IL4I1 by ZY-MY-111 reactivates CD8+ T cell immunity and suppresses tumor growth"],"prefix":"10.1038","volume":"47","author":[{"given":"Ju-fei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-hao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-pei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-chao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"1843_CR1","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","volume":"182","author":"A Sadik","year":"2020","unstructured":"Sadik A, Somarribas Patterson LF, Ozturk S, Mohapatra SR, Panitz V, Secker PF, et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell. 2020;182:1252\u201370.e34.","journal-title":"Cell"},{"key":"1843_CR2","doi-asserted-by":"crossref","unstructured":"Zeitler L, Murray PJ. IL4i1 and IDO1: oxidases that control a tryptophan metabolic nexus in cancer. J Biol Chem. 2023;299:104827.","DOI":"10.1016\/j.jbc.2023.104827"},{"key":"1843_CR3","doi-asserted-by":"crossref","unstructured":"Hirose S, Mashima T, Yuan X, Yamashita M, Kitano S, Torii S, et al. Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8+ T cell infiltration in melanoma. Cancer Sci. 2024;115:791\u2013803.","DOI":"10.1111\/cas.16073"},{"key":"1843_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1924500","volume":"10","author":"F Castellano","year":"2021","unstructured":"Castellano F, Prevost-Blondel A, Cohen JL, Molinier-Frenkel V. What role for AHR activation in IL4I1-mediated immunosuppression. Oncoimmunology. 2021;10:1924500.","journal-title":"Oncoimmunology"},{"key":"1843_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06028-3","volume":"23","author":"R Zhang","year":"2025","unstructured":"Zhang R, Zhang Y, Xiao H, Liu Q, Zhao M. Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed\/refractory diffuse large B-cell lymphoma. J Transl Med. 2025;23:105.","journal-title":"J Transl Med"},{"key":"1843_CR6","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell. 2017;171:934\u201349.e16.","journal-title":"Cell"},{"key":"1843_CR7","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11:3696\u2013713.","journal-title":"J Chem Theory Comput"},{"key":"1843_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/wcms.81","volume":"2","author":"F Neese","year":"2012","unstructured":"Neese F. The ORCA program system. WIREs Comput Mol Sci. 2012;2:73\u20138.","journal-title":"WIREs Comput Mol Sci"},{"key":"1843_CR9","doi-asserted-by":"crossref","unstructured":"Lu T. A comprehensive electron wavefunction analysis toolbox for chemists, Multiwfn. J Chem Phys. 2024;161:082503.","DOI":"10.1063\/5.0216272"},{"key":"1843_CR10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25:1157\u201374.","journal-title":"J Comput Chem"},{"key":"1843_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-021-00529-z","volume":"6","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li T, Mao C, Liu W, Tao Y. IL4I1-driven AHR signature: a new avenue for cancer therapy. Signal Transduct Target Ther. 2021;6:118.","journal-title":"Signal Transduct Target Ther"},{"key":"1843_CR12","doi-asserted-by":"crossref","unstructured":"Boulland ML, Marquet J, Molinier-Frenkel V, Moller P, Guiter C, Lasoudris F, et al. Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation. Blood. 2007;110:220\u20137.","DOI":"10.1182\/blood-2006-07-036210"},{"key":"1843_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103049","volume":"138","author":"W Huang","year":"2023","unstructured":"Huang W, Rui K, Wang X, Peng N, Zhou W, Shi X, et al. The aryl hydrocarbon receptor in immune regulation and autoimmune pathogenesis. J Autoimmun. 2023;138:103049.","journal-title":"J Autoimmun"},{"key":"1843_CR14","doi-asserted-by":"crossref","unstructured":"Romagnani S. IL4I1: key immunoregulator at a crossroads of divergent T-cell functions. Eur J Immunol. 2016;46:2302\u20135.","DOI":"10.1002\/eji.201646617"},{"key":"1843_CR15","doi-asserted-by":"crossref","unstructured":"Lasoudris F, Cousin C, Prevost-Blondel A, Martin-Garcia N, Abd-Alsamad I, Ortonne N, et al. IL4I1: an inhibitor of the CD8+ antitumor T-cell response in vivo. Eur J Immunol. 2011;41:1629\u201338.","DOI":"10.1002\/eji.201041119"},{"key":"1843_CR16","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1182\/blood-2002-07-2215","volume":"101","author":"C Copie-Bergman","year":"2003","unstructured":"Copie-Bergman C, Boulland ML, Dehoulle C, Moller P, Farcet JP, Dyer MJ, et al. Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood. 2003;101:2756\u201361.","journal-title":"Blood"},{"key":"1843_CR17","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/leu.2008.380","volume":"23","author":"A Carbonnelle-Puscian","year":"2009","unstructured":"Carbonnelle-Puscian A, Copie-Bergman C, Baia M, Martin-Garcia N, Allory Y, Haioun C, et al. The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages. Leukemia. 2009;23:952\u201360.","journal-title":"Leukemia"},{"key":"1843_CR18","doi-asserted-by":"crossref","unstructured":"Molinier-Frenkel V, Prevost-Blondel A, Castellano F. The IL4I1 enzyme: a new player in the immunosuppressive tumor microenvironment. Cells. 2019;8:757.","DOI":"10.3390\/cells8070757"},{"key":"1843_CR19","doi-asserted-by":"crossref","unstructured":"Grobben Y. Targeting amino acid-metabolizing enzymes for cancer immunotherapy. Front Immunol. 2024;15:1440269.","DOI":"10.3389\/fimmu.2024.1440269"},{"key":"1843_CR20","doi-asserted-by":"crossref","unstructured":"Stone TW, Williams RO. Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends Pharmacol Sci. 2023;44:442\u201356.","DOI":"10.1016\/j.tips.2023.04.006"},{"key":"1843_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.coi.2020.12.003","volume":"70","author":"D Leclerc","year":"2021","unstructured":"Leclerc D, Staats Pires AC, Guillemin GJ, Gilot D. Detrimental activation of AhR pathway in cancer: an overview of therapeutic strategies. Curr Opin Immunol. 2021;70:15\u201326.","journal-title":"Curr Opin Immunol"},{"key":"1843_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70274","volume":"6","author":"P Gao","year":"2025","unstructured":"Gao P, Li X, Duan Z, Wang Y, Li Y, Wang J, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade: advances in molecular mechanisms and therapeutic strategies. MedComm. 2025;6:e70274.","journal-title":"MedComm"},{"key":"1843_CR23","doi-asserted-by":"crossref","unstructured":"Van den Eynde BJ, van Baren N, Baurain JF. Is there a clinical future for IDO1 inhibitors after the failure of Epacadostat in melanoma? Annu Rev Cancer Biol. 2020;4:241\u201356.","DOI":"10.1146\/annurev-cancerbio-030419-033635"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01843-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01843-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01843-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:04:35Z","timestamp":1787040275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01843-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01843-4","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}